Considering the role of m6A modification and its erasers in carcinogenesis, we hypothesized that demethylating enzymes, FTO and ALKBH5, might be potential biomarkers with distinct roles in different RCC subtypes and oncocytomas. The gene discussed is FTO; the disease is oncocytic adenoma.